常德生物医药的差异化突围：如何探索中部产业化答案？

Core Insights - Changde is exploring a differentiated development path in the biopharmaceutical industry, focusing on "pilot transformation" rather than following the crowded front-end R&D in advanced regions [1][7] - The city has established itself as a significant production base for biological enzyme preparations and steroid raw materials, leveraging its 60 years of fermentation industry experience [1][3] - Changde's biomanufacturing sector has shown strong growth, with 35 synthetic biological manufacturing enterprises achieving a total output value of over 12.5 billion yuan in 2024, reflecting a year-on-year growth of 24.01% in the first eight months of 2025 [2][7] Industry Development - Changde has built a comprehensive pilot platform for biomanufacturing, which includes multiple production lines covering fermentation, separation, purification, and refinement, equipped with various pilot fermentation tanks [3][6] - The local government has introduced supportive policies, including the first local regulations in the biomanufacturing sector and targeted initiatives to foster industry breakthroughs [3][4] - The city has attracted key enterprises like Lier Bio and Muen Bio, which have reported significant growth rates of 103.9% and 101.1% respectively, indicating a robust development momentum [2][6] Strategic Initiatives - Changde is implementing a series of practical measures to support innovation, such as a 15-year guidance fund for startups and a 2.3 million-ton contract manufacturing capacity for growth-stage companies [4][5] - The establishment of the Hunan Synthetic Biomanufacturing Industry Innovation Center focuses on foundational technology research, providing common technical support for enterprises [6][7] - The city is transitioning from a manufacturing to an intelligent manufacturing model, with a notable increase in R&D expenditure by 16.1%, showcasing strong innovation vitality [7]